143 related articles for article (PubMed ID: 26994504)
21. Bivalirudin use and one-month outcome in the context of contemporary antiplatelet treatment: insights from the Greek Antiplatelet Registry.
Alexopoulos D; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Karayannis G; Angelidis C; Stavrou K; Vavuranakis M; Goudevenos JA; Stefanadis C;
Cardiovasc Ther; 2014 Jun; 32(3):120-6. PubMed ID: 24512682
[TBL] [Abstract][Full Text] [Related]
22. Comparison of heparin and bivalirudin in patients undergoing percutaneous coronary intervention without use of glycoprotein IIb/IIIa inhibitors.
Abtahian F; Waldo S; Jang IK
Catheter Cardiovasc Interv; 2015 Sep; 86(3):390-6. PubMed ID: 25753749
[TBL] [Abstract][Full Text] [Related]
23. Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients.
Rao SV; Dai D; Subherwal S; Weintraub WS; Brindis RS; Messenger JC; Lopes RD; Peterson ED
JACC Cardiovasc Interv; 2012 Sep; 5(9):958-65. PubMed ID: 22995883
[TBL] [Abstract][Full Text] [Related]
24. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry.
Lopes RD; Peterson ED; Chen AY; Roe MT; Wang TY; Ohman EM; Magid DJ; Ho PM; Wiviott SD; Scirica BM; Alexander KP
JACC Cardiovasc Interv; 2010 Jun; 3(6):669-77. PubMed ID: 20630461
[TBL] [Abstract][Full Text] [Related]
25. Patterns of use and comparative effectiveness of bleeding avoidance strategies in men and women following percutaneous coronary interventions: an observational study from the National Cardiovascular Data Registry.
Daugherty SL; Thompson LE; Kim S; Rao SV; Subherwal S; Tsai TT; Messenger JC; Masoudi FA
J Am Coll Cardiol; 2013 May; 61(20):2070-8. PubMed ID: 23524046
[TBL] [Abstract][Full Text] [Related]
26. Bivalirudin started during emergency transport for primary PCI.
Steg PG; van 't Hof A; Hamm CW; Clemmensen P; Lapostolle F; Coste P; Ten Berg J; Van Grunsven P; Eggink GJ; Nibbe L; Zeymer U; Campo dell' Orto M; Nef H; Steinmetz J; Soulat L; Huber K; Deliargyris EN; Bernstein D; Schuette D; Prats J; Clayton T; Pocock S; Hamon M; Goldstein P;
N Engl J Med; 2013 Dec; 369(23):2207-17. PubMed ID: 24171490
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN
J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573
[TBL] [Abstract][Full Text] [Related]
28. Comparison of bivalirudin and radial access across a spectrum of preprocedural risk of bleeding in percutaneous coronary intervention: analysis from the national cardiovascular data registry.
Baklanov DV; Kim S; Marso SP; Subherwal S; Rao SV
Circ Cardiovasc Interv; 2013 Aug; 6(4):347-53. PubMed ID: 23922144
[TBL] [Abstract][Full Text] [Related]
29. Safety of bivalirudin in percutaneous coronary intervention following thrombolytic therapy.
Sardi GL; Lindsay J; Waksman R
Catheter Cardiovasc Interv; 2013 Oct; 82(4):614-20. PubMed ID: 22581418
[TBL] [Abstract][Full Text] [Related]
30. Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice.
Showkathali R; Davies JR; Parker M; Taggu W; Tang KH; Clesham GJ; Gamma RA; Sayer JW; Aggarwal RK; Kelly PA
Cardiovasc Revasc Med; 2013; 14(5):289-93. PubMed ID: 23972537
[TBL] [Abstract][Full Text] [Related]
31. Heparin is Not Inferior to Bivalirudin in Percutaneous Coronary Intervention-Focusing on the Effect of Glycoprotein IIb/IIIa Inhibitor Use: A Meta-Analysis.
Huang FY; Huang BT; Peng Y; Liu W; Zhao ZG; Wang PJ; Zuo ZL; Zhang C; Liao YB; Luo XL; Meng QT; Chen C; Huang KS; Chai H; Li Q; Chen M; Zhu Y
Angiology; 2015 Oct; 66(9):845-55. PubMed ID: 25635117
[TBL] [Abstract][Full Text] [Related]
32. Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.
Geisler T; Müller K; Karathanos A; Bocksch W; Gawaz M; Deliargyris E; Bernstein D; Lincoff AM; Mehran R; Dangas G; Stone GW
EuroIntervention; 2014 May; 10(1):97-104. PubMed ID: 24048204
[TBL] [Abstract][Full Text] [Related]
33. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL
Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538
[TBL] [Abstract][Full Text] [Related]
34. Use of low-dose heparin with bivalirudin for ad-hoc transradial coronary interventions: experience from a single center.
Singh A; Edasery D; Noor A; Bhasin N; Kaplan B; Jauhar R
J Invasive Cardiol; 2011 Mar; 23(3):101-4. PubMed ID: 21364238
[TBL] [Abstract][Full Text] [Related]
35. The bivalirudin paradox: high evidence, low use.
De Servi S; Mariani G; Mariani M; D'Urbano M
J Cardiovasc Med (Hagerstown); 2013 May; 14(5):334-41. PubMed ID: 23442811
[TBL] [Abstract][Full Text] [Related]
36. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW;
JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052
[TBL] [Abstract][Full Text] [Related]
37. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
38. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
[TBL] [Abstract][Full Text] [Related]
39. Bivalirudin during primary PCI in acute myocardial infarction.
Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Kirtane AJ; Parise H; Mehran R;
N Engl J Med; 2008 May; 358(21):2218-30. PubMed ID: 18499566
[TBL] [Abstract][Full Text] [Related]
40. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention.
Marso SP; Amin AP; House JA; Kennedy KF; Spertus JA; Rao SV; Cohen DJ; Messenger JC; Rumsfeld JS;
JAMA; 2010 Jun; 303(21):2156-64. PubMed ID: 20516416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
